Related Experiment Video

Updated: Aug 12, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K

Clinicopathologic and Molecular Subtyping of EGFR Mutation-Response

Hyun Ae Jung1, Jinyeong Lim2, Yoon-La Choi3

  • 1Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 1, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Related Experiment Videos

Last Updated: Aug 12, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K

Articles linked to this work by shared authors, journal, and citation graph.

A Noncanonical MET Exon 14 Splice-Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib.

Thoracic cancer·2026

Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non-Small Cell Lung Cancer.

Cancer research communications·2026

Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.

JCO global oncology·2026

SHEST: single-cell-level artificial intelligence from haematoxylin and eosin morphology for cell-type prediction and spatial transcriptomics reconstruction.

Briefings in bioinformatics·2026

Deep Learning Predicts EGFR Mutation Status from Histology Images in Non-Small Cell Lung Cancer.

Cancer research communications·2025

Deep-Learning Model for Real-Time Prediction of Recurrence in Early-Stage Non-Small Cell Lung Cancer: A Multimodal Approach (RADAR CARE Study).

JCO precision oncology·2025

Whole Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

BRIGHTLINE-1: When a Negative Trial Reveals Two Active Therapies.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

EZH2 Inhibition and Myeloid Risk: A Feature of On-Target Biology.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us